← Leaderboards
Daqing Wu
Emory University
$4,945,014
Attributed
$4,945,014
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,332,375 · 8
By mechanism
U54$4,768,122 · 2
R42$1,935,175 · 1
R01$1,655,250 · 1
R41$610,994 · 3
R21$362,834 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Nelson M Oyesiku$1,701,549
- Matam Vijay-Kumar$4,492,689
- Ruoxiang Wang$472,425
- Allan I Levey$89,469,218
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateIn VivoPharmaceutical PreparationsSignal TransductionPre-Clinical ModelPre-ClinicalDoseGrowthMortalityUniversitiesToxic EffectSafetyCancer PatientProstate Cancer CellPropertyTherapeutic DevelopmentInnovationDrug DiscoveryLeadNci Center For Cancer ResearchResearch And DevelopmentDrug KineticsProstate Cancer TherapyXenograft Model
Grant awards (19)
Targeting chemoresistant prostate cancer with novel EED inhibitors$428,304
R01 · FY2025 · CA · contact PI
RESEARCH PROJECT 1: DAQING WU$184,411
U54 · FY2025 · MD · contact PI
RESEARCH PROJECT 1: DAQING WU$196,350
U54 · FY2024 · MD · contact PI
Targeting chemoresistant prostate cancer with novel EED inhibitors$104,961
R01 · FY2024 · CA · contact PI
Targeting chemoresistant prostate cancer with novel EED inhibitors$56,208
R01 · FY2024 · CA · contact PI
Enhancement of Cancer Research at Clark Atlanta University$2,726,079
U54 · FY2023 · MD · contact PI
Targeting chemoresistant prostate cancer with novel EED inhibitors$463,429
R01 · FY2023 · CA · contact PI
Diversity Supplement: Targeting chemoresistant prostate cancer with novel EED inhibitors$59,167
R01 · FY2023 · CA · contact PI
Enhancement of Cancer Research at Clark Atlanta University$1,546,132
U54 · FY2022 · MD · contact PI
Small-molecule therapy for metastatic castration-resistant prostate cancer$927,358
R42 · FY2022 · CA · contact PI
Targeting chemoresistant prostate cancer with novel EED inhibitors$543,181
R01 · FY2022 · CA · contact PI
Enhancement of Cancer Research at Clark Atlanta University$115,150
U54 · FY2022 · MD · contact PI
Small-molecule therapy for metastatic castration-resistant prostate cancer$1,007,817
R42 · FY2021 · CA · contact PI
Small-molecule therapy for metastatic prostate cancer$224,999
R41 · FY2017 · CA · contact PI
Novel small-molecule targeted therapy for prostate cancer$224,999
R41 · FY2016 · CA · contact PI
A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate Cancer$160,996
R41 · FY2015 · CA · contact PI
EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis$103,833
R21 · FY2013 · CA · contact PI
EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis$55,638
R21 · FY2013 · CA · contact PI
EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis$203,363
R21 · FY2012 · CA · contact PI